Research Reports | Market Assessment
December 2016

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | US/EU | 2016

The therapeutic landscape for second-line chronic lymphocytic leukemia (CLL) has benefited from the introduction of three new therapies since 2014, namely, Imbruvica, Venclexta, and Zydelig. Although these agents have improved the treatment outcomes considerably, most patients eventually stop responding and ultimately die of their disease. The currently available second-line CLL therapies are moderately satisfying in terms of efficacy, safety and tolerability, convenience of administration, and non-clinical factors, yet the remaining unmet need for more-efficacious and better-tolerated therapies presents a significant commercial opportunity

 

 

 

 

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports